BeOne Medicines AG (ONC) Stock Analysis
Verdict: HOLD
Surging commercial sales of BRUKINSA fuel profitable scale, but elevated trailing multiples leave narrow room for execution slippage.
Investment score: 63/100
Analysis as of
Is BeOne Medicines AG stock worth reviewing? The TradeMates thesis
The TradeMates model assesses BeOne Medicines as a high-quality commercial oncology powerhouse. Strong top-line execution (+34% Q3 revenue) and robust cash generation ($861M FY25 FCF) are balanced by high sales multiples (P/S 53.6x), supporting a Hold recommendation.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 88/100 (weight 15%)
- Technical Momentum: 72/100 (weight 15%)
- Earnings Quality: 82/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 62/100 (weight 15%)
BeOne Medicines AG opportunities and risks
What speaks for ONC
- Commercial Scale of BRUKINSA
What speaks against ONC
- Product Concentration Risk
Frequently asked questions about BeOne Medicines AG (ONC)
Is ONC stock a good investment?
The TradeMates model rates BeOne Medicines AG as HOLD with an investment score of 63/100. The TradeMates model assesses BeOne Medicines as a high-quality commercial oncology powerhouse. Strong top-line execution (+34% Q3 revenue) and robust cash generation ($861M FY25 FCF) are balanced by high sales multiples (P/S 53.6x), supporting a Hold recommendation. This is algorithmic model output, not personal investment advice.
Is ONC stock a buy?
The TradeMates model verdict for ONC is HOLD with an investment score of 63/100. Treat this as a model signal to review, not a personal buy recommendation.